ADMA ADMA Biologics, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ADMA Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$16.09
Analyst Target
$25.67
+59.5%
Upside
52W High
$25.67
52W Low
$13.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$3.84B
P/E
18.08
ROE
63.2%
Profit margin
42.9%
Debt/Equity
0.19
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress in operational efficiency and profitability sustainability. Despite strong margins and ROE, the company shows stagnant earnings growth (0% YoY) and a recent decline in technical momentum, with a 12% drop in the past month. Insider selling totaling $1.43M over six months, particularly from the CEO, raises red flags about internal confidence. The stock trades at a premium to its Graham Number ($6.02) and intrinsic value ($6.23), suggesting overvaluation given its current growth profile. Analysts have not issued a formal recommendation, but the target price of $25.67 implies a significant upside, which may not be justified by fundamentals.
Key Strengths
Exceptionally high profit margins (54.71% gross, 42.87% net)
Strong ROE of 63.17% indicates efficient use of equity
Very low debt/equity ratio (0.19) and high current ratio (7.13) reflect strong financial health
Consistent positive earnings surprises in prior quarters (e.g., +62.5%, +60.0%)
Significant long-term price appreciation (507% over 5 years)
Key Risks
Piotroski F-Score of 3/9 indicates weak financial stability and operational inefficiency
Zero earnings growth (0% YoY) despite revenue growth of 12.00%
Recent insider selling by CEO (4 transactions of 21,000 shares each) signals bearish sentiment
Stock trades at $16.09, significantly above Graham Number ($6.02) and intrinsic value ($6.23)
No analyst consensus or target price guidance, indicating lack of institutional confidence
AI Fair Value Estimate
Based on comprehensive analysis
$6.23
-61.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
34
Weak
30
45
65
30
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (3/9), Stagnant earnings growth, Overvaluation relative to intrinsic value, Bearish insider activity, Lack of analyst coverage
Confidence
88%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- High profit margins and ROE suggest strong underlying profitability
- Low debt/equity ratio supports value stability
Watchpoints
- Current price ($16.09) is over 2.5x the Graham Number ($6.02)
- Intrinsic value estimate ($6.23) is significantly below market price
- No PEG ratio available, limiting growth-adjusted valuation
Future
45/100
Ref Growth rates
Positives
- 12.00% revenue growth (YoY) indicates top-line expansion
- Recent Q/Q EPS growth of +14.3% shows improving momentum
Watchpoints
- Earnings growth is flat (0% YoY)
- No forward PEG ratio available, limiting growth assessment
- Analyst target price ($25.67) is not supported by current earnings trends
Past
65/100
Ref Historical trends
Positives
- Consistent earnings beat history (2/4 in last 4 quarters)
- Strong historical EPS progression with multiple large positive surprises
- 5-year price return of +507% reflects strong investor confidence
Watchpoints
- Recent earnings misses (e.g., -33.3% surprise in Q1 2025)
- Negative EPS in multiple prior quarters, indicating early-stage losses
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Extremely low debt/equity (0.19)
- High current and quick ratios (7.13 and 3.52) indicate strong liquidity
Watchpoints
- Piotroski F-Score of 3/9 signals weak financial health
- No Altman Z-Score available, but F-Score below 4 implies distress risk
- Lack of cash flow data raises concerns about sustainability
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength: 0/100
- Payout Ratio: 0.00%
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$16.09
Analyst Target
$25.67
Upside/Downside
+59.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADMA and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
Primary
|
+507.2% | +348.2% | +0.1% | -5.3% | -12.0% | -2.1% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-55.1% | +15.3% | +11.4% | -13.0% | -18.0% | -6.5% |
|
ACLX
Arcellx, Inc.
Peer
|
+307.7% | +127.2% | +7.5% | -7.5% | -1.9% | +0.7% |
|
BLLN
BillionToOne, Inc.
Peer
|
-19.6% | -19.6% | -19.6% | -19.6% | +1.4% | -1.3% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+176.1% | +531.6% | +52.0% | +66.1% | +4.0% | -0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
18.08
Forward P/E
17.12
PEG Ratio
N/A
P/B Ratio
8.89
P/S Ratio
7.86
EV/Revenue
7.88
EV/EBITDA
22.0
Market Cap
$3.84B
Profitability
Profit margins and return metrics
Profit Margin
42.87%
Operating Margin
38.01%
Gross Margin
54.71%
ROE
63.17%
ROA
21.76%
Growth
Revenue and earnings growth rates
Revenue Growth
+12.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+1.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.19
Low debt
Current Ratio
7.13
Strong
Quick Ratio
3.52
Excellent
Cash/Share
$0.26
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-02
$N/A
2025-11-05
$0.16
+2.6% surprise
2025-08-06
$0.14
+7.4% surprise
2025-05-07
$0.11
-33.3% surprise
Healthcare Sector Comparison
Comparing ADMA against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
P/E Ratio
18.08
This Stock
vs
197.69
Sector Avg
-90.9%
(Discount)
Return on Equity (ROE)
63.17%
This Stock
vs
-56.84%
Sector Avg
-211.1%
(Below Avg)
Profit Margin
42.87%
This Stock
vs
-20.8%
Sector Avg
-306.1%
(Weaker)
Debt to Equity
0.19
This Stock
vs
2.68
Sector Avg
-92.8%
(Less Debt)
Revenue Growth
12.0%
This Stock
vs
61.93%
Sector Avg
-80.6%
(Slower)
Current Ratio
7.13
This Stock
vs
3.47
Sector Avg
+105.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.84B | 18.08 | 63.2% | 42.9% | $16.09 | |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
BULLISH | $3.73B | 13.94 | 35.0% | 24.9% | $22.03 | |
|
ACLX
Arcellx, Inc.
|
BEARISH | $3.96B | - | -47.2% | -% | $68.5 | |
|
BLLN
BillionToOne, Inc.
|
NEUTRAL | $4.01B | - | -% | -4.4% | $87.57 | |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
NEUTRAL | $4.21B | 1339.0 | -% | 0.2% | $13.39 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-09 | GROSSMAN ADAM S | Chief Executive Officer | Stock Award | 282,529 | - |
| 2026-02-09 | GUIHEEN LAWRENCE P | Director | Stock Award | 10,690 | - |
| 2026-02-09 | FINGER ALISON CECILY | Director | Stock Award | 10,690 | - |
| 2026-02-09 | KWON YOUNG T. PH.D. | Director | Stock Award | 10,690 | - |
| 2026-02-09 | SALAS EDUARDO RENE | Director | Stock Award | 10,690 | - |
| 2026-02-09 | KESTENBERG-MESSINA KAITLIN M. | Officer | Stock Award | 91,631 | - |
| 2026-02-09 | GROSSMAN JERROLD B | Director | Stock Award | 10,690 | - |
| 2025-12-15 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $415,590 |
| 2025-12-15 | GROSSMAN ADAM S | Chief Executive Officer | Option Exercise | 15,000 | $81,000 |
| 2025-11-19 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $336,000 |
| 2025-11-19 | GROSSMAN ADAM S | Chief Executive Officer | Option Exercise | 15,000 | $81,000 |
| 2025-10-24 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $336,000 |
| 2025-10-24 | GROSSMAN ADAM S | Chief Executive Officer | Option Exercise | 15,000 | $81,000 |
| 2025-09-15 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $338,730 |
| 2025-09-15 | GROSSMAN ADAM S | Chief Executive Officer | Option Exercise | 15,000 | $81,000 |
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning ADMA from our newsroom.
Newest → oldest
No matching news yet.